2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Mb02: new trials by email Literature Review of Mb02 trials Research Report on Mb02
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Bevacizumab, Ipilimumab - Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 169 | 2014-01-24 | 2025-12-11 |
| Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Bevacizumab, Carboplatin, Cyclophosphamide - Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 454 | 2009-07-21 | 2026-06-29 |
Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Melanoma (1) · Triple Negative Breast Neoplasms (1)
National Cancer Institute (NCI) (2)
United States (2)
Frank S Hodi (1) · William M Sikov (1)
PMID 25092775, PMID 35044810, PMID 42550611
U10CA021115 (1), U10CA031946 (1), U10CA180820 (1), U10CA180821 (1), U24CA196172 (1)